What the FDA labels say about taking them together
Atorvastatin and ethinyl estradiol/levonorgestrel
Ethinyl estradiol/levonorgestrel's FDA label of August 27, 2026 names atorvastatin in its drug interactions section; the atorvastatin labels PlainMeds reads (2) do not name ethinyl estradiol/levonorgestrel. The ethinyl estradiol/levonorgestrel label: “Substances increasing the plasma concentrations of COCs: Co-administration of atorvastatin or rosuvastatin and certain COCs containing EE increase AUC values for EE by approximately 20-25%.”
Check it at the source: the atorvastatin FDA label on DailyMed (effective April 15, 2024, Viatris Specialty LLC); the ethinyl estradiol/levonorgestrel FDA label on DailyMed (effective August 27, 2026, Exeltis USA, Inc.).
What does the atorvastatin label say about ethinyl estradiol/levonorgestrel?
Atorvastatin's label (effective April 15, 2024) and its 1 other brand-application label do not name ethinyl estradiol/levonorgestrel in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Lipitor), NDA020702 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2024 (SPL set a60cc18b-0631-4cf0-b021-9f52224ece65), via openFDA; the full label on DailyMed
What does the ethinyl estradiol/levonorgestrel label say about atorvastatin?
Ethinyl estradiol/levonorgestrel label, drug interactionsSubstances increasing the systemic exposure of CHCs: Co-administration of atorvastatin or rosuvastatin and CHCs containing ethinyl estradiol increase systemic exposure of ethinyl estradiol by approximately 20 to 25 percent.
Balcoltra label (Avion Pharmaceuticals, December 5, 2025), drug interactionsSubstances increasing the plasma concentrations of COCs: Co-administration of atorvastatin or rosuvastatin and certain COCs containing EE increase AUC values for EE by approximately 20-25%.
Source: FDA drug label (Balcoltra, NDA208612), Avion Pharmaceuticals, effective December 5, 2025 (SPL set 752ab698-4b48-4614-8016-d1d33ee7c007), via openFDA
Source: FDA drug label (Tyblume), Exeltis USA, Inc., effective August 27, 2026 (SPL set b2482d51-d606-4aaa-8af4-19e4fe2f8872), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atorvastatin | Ethinyl estradiol/levonorgestrel | |
|---|---|---|
| Labeled for | High cholesterol, Angina, High triglycerides, Heart attack and coronary artery disease | Birth control |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0228 per tablet 10 mg tablet | $0.154 per tablet 28 tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once